A Randomized Clinical Trial of Che Motherapy Combined with Oxaliplatin and Cisplatin Plus Paclitaxel in the Treatment of Advanced Non-small Cell Lung Cancer

Objective Observation the difference of efficacy,side effects and quality of life in advanced non small cell lung cancer(NSCLC) patients treated with Paclitaxel plus oxaliplatin or cisplatin.Methods The 50 patients with advanced NSCLC were divided into two groups.25 patients in control group,paclitaxel 135mg/m2,d1,d8;cisplatin 75mg/m2,d1-d2.25 patients with oxaliplatin,paclitaxel with cisplatin use,oxaliplatin 130 mg/m2,d1,both intravenous infusion,21d of a course of treatment.Evaluation of efficiency,adverse reactions and quality of life.Results The rates of Control group and treatment group,were 20% and 48%,the difference was statistically significant(P0.05).the incidence of gastrointestinal reactions were higher in Control group than those in treatment group(P0.05).While in peripheral nerve toxicity,the oxaliplatin group was higher than the cisplatin group(P0.05),in Quality of life,the KPS of treatment group score higher than those in treatment group(P0.05).Conclusion Paclitaxel and oxaliplatin are an effective program of treatment of advanced NSCLC.Side effects is small,especially inGastrointestinal reactions,it is weak,the program accepted easily by patients,have a high compliance,can significantly improve the patients quality of life.